Retracted
This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
PMC · DOI:10.1007/s00280-023-04587-8·September 16, 2023
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya, Yutaka Okayama
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRenal cell carcinoma treatment